Go to the list of all blogs
Arthur Evans's Avatar
published in Blogs
Nov 20, 2026
TickeronGET DAILY SIGNALS
Rhythm Pharmaceuticals (RYTM) Rises +29.5% in 30 Days on Earnings Strength and Takeover Interest

Rhythm Pharmaceuticals (RYTM) Rises +29.5% in 30 Days on Earnings Strength and Takeover Interest

Key Takeaways

  • Rhythm Pharmaceuticals (RYTM) shares climbed roughly 29.5% over the last 30 days, rising from about $90.20 to a closing price near $116.80.
  • The move was driven by strong third-quarter 2026 results and reports that AstraZeneca made a takeover approach valuing the company near $10 billion.
  • Third-quarter net product revenue reached $92.1 million, up 79.6% year over year, led by the U.S. launch of IMCIVREE for acquired hypothalamic obesity.
  • Two-year Phase 3 TRANSCEND trial data reinforced the durability of IMCIVREE's effect, prompting analyst price-target increases.
  • Over the last quarter the stock is up only modestly on a net basis, reflecting a sharp drawdown in early November followed by a rapid recovery.
  • Investors can review additional Price Targets, Earnings, and Forecast data on dedicated pages.

Rhythm Pharmaceuticals (RYTM) Company Overview and Market Position

Rhythm Pharmaceuticals is a commercial-stage biopharmaceutical company focused on rare neuroendocrine diseases and genetic forms of severe obesity. Its lead product, IMCIVREE (setmelanotide), is a melanocortin-4 receptor (MC4R) agonist approved for chronic weight management in patients with specific genetic deficiencies, including Bardet-Biedl syndrome and acquired hypothalamic obesity.

In March 2026, the FDA expanded IMCIVREE's approval to treat acquired hypothalamic obesity, making it the first therapy approved in the U.S. for that condition. The company has since built a growing commercial footprint across the U.S., Japan, and Europe, while advancing a pipeline that includes bivamelagon and RM-718, along with studies in Prader-Willi syndrome. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

Rhythm Pharmaceuticals (RYTM) Stock Price Performance: Last 30 Days vs. Quarter

Over the last 30 days, RYTM advanced approximately 29.5%, moving from about $90.20 to roughly $116.80. The largest single-day gain occurred on November 4, 2026, when the stock jumped about 28% following reports of a takeover approach from AstraZeneca.

The last quarter tells a more volatile story. Over the trailing three months, the stock is up only about 6% on a net basis. Shares traded near $110 in late August before pulling back into early November, when the price briefly fell below $87. The subsequent surge on M&A speculation and strong commercial results produced a sharp V-shaped recovery, but the broader quarterly trend remains more moderate than the recent 30-day move suggests.

What Drove RYTM Stock Price in the Last 30 Days

Several catalysts converged to fuel the rally. First, on November 3, Rhythm reported third-quarter 2026 net product revenue of $92.1 million, beating consensus estimates and growing 79.6% year over year. The U.S. launch of IMCIVREE for acquired hypothalamic obesity was the primary growth driver, with more than 700 patient start forms received since launch.

Second, reports emerged that AstraZeneca had submitted a non-binding takeover proposal of roughly $10 billion, with a reported offer around $124 per share and up to $134 per share including milestone payments. Deal-focused media subsequently reported the possible involvement of additional bidders, including Eli Lilly (LLY), further lifting sentiment. Neither company has publicly confirmed a transaction.

Third, on November 17, Rhythm presented two-year data from the Phase 3 TRANSCEND trial showing an 18.8% reduction in a key clinical endpoint at two years versus 16.5% at one year. Analysts at Canaccord called the results "incrementally positive," and the stock rose about 9% on the day. These developments were accompanied by price-target increases from firms including Canaccord and Citizens. From what I see, the combination of these factors created meaningful momentum.

What Drove RYTM Stock Performance Over the Last Quarter

The quarterly narrative centers on the commercial expansion of IMCIVREE. The U.S. launch in acquired hypothalamic obesity continued to gain momentum, with steady prescription growth, a broadening base of prescribers, and expanding payer coverage reaching roughly 75% of commercial lives. Rhythm also launched IMCIVREE in Japan in October 2026, establishing a second major commercial market.

The stock's early-quarter weakness reflected broader volatility in the biotechnology sector and profit-taking after a strong run. The recovery was driven less by a single fundamental event than by the combination of accelerating revenue, favorable trial data, and takeover speculation. The company also announced a renegotiated royalty agreement with LG Chem for bivamelagon, reducing long-term royalty obligations while advancing the next-generation MC4R portfolio.

RYTM Stock Forecast Drivers: What Investors Should Watch Next

Looking ahead, investors are likely to monitor the continued pace of the U.S. IMCIVREE launch, including patient start forms, reimbursement trends, and prescription conversion rates. International expansion is another key variable, with European launches expected during 2027 and Japan's contribution expected to grow once prescription restrictions ease.

On the clinical front, Rhythm plans to advance bivamelagon into Phase 3 trials in acquired hypothalamic obesity, with first dosing expected in early 2027, and to pursue a Phase 3 program in Prader-Willi syndrome. The resolution of takeover speculation, whether through a confirmed transaction or a withdrawal of interest, could also influence the stock. The company's cash position, operating-loss trajectory, and fourth-quarter results, expected in February 2027, remain important data points for evaluating the durability of the recent advance. I’m watching this closely as the clinical and commercial updates unfold.

Using Tickeron AI Tools in My Analysis

In my research process, I often turn to Tickeron’s AI Trading Bots to test automated approaches on names like RYTM. These tools help simulate strategies across different timeframes and risk levels, providing another layer of perspective alongside traditional fundamental review. This approach has proven practical for identifying patterns in volatile biotech names without replacing core analysis.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: RYTM

Contributor

Financial writer and active order flow futures trader with a focus on fundamental analysis, macroeconomic factors, and equity research. I make in-depth blogs on stocks and ETFs, bridging the gap between raw market data and real-world trading decisions.


RYTM in upward trend: 10-day moving average moved above 50-day moving average on November 06, 2026

The 10-day moving average for RYTM crossed bullishly above the 50-day moving average on November 06, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 13 of 16 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 81%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on November 04, 2026. You may want to consider a long position or call options on RYTM as a result. In 59 of 75 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 79%.

The Moving Average Convergence Divergence (MACD) for RYTM just turned positive on October 20, 2026. Looking at past instances where RYTM's MACD turned positive, the stock continued to rise in 37 of 46 cases over the following month. The odds of a continued upward trend are 80%.

RYTM moved above its 50-day moving average on November 04, 2026 date and that indicates a change from a downward trend to an upward trend.

The 50-day moving average for RYTM moved above the 200-day moving average on November 18, 2026. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.

Following a +10.76% 3-day Advance, the price is estimated to grow further. Considering data from situations where RYTM advanced for three days, in 237 of 294 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.

Bearish Trend Analysis

The 10-day RSI Indicator for RYTM moved out of overbought territory on November 11, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 31 similar instances where the indicator moved out of overbought territory. In 29 of the 31 cases, the stock moved lower in the following days. This puts the odds of a move lower at 90%.

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 10 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where RYTM declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 74%.

RYTM broke above its upper Bollinger Band on November 06, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for RYTM entered a downward trend on October 23, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Profit vs. Risk Rating rating for this company is 10 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.

The Tickeron Price Growth Rating for this company is 36 (best 1 - 100 worst), indicating steady price growth. RYTM’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron PE Growth Rating for this company is 57 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 92 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: RYTM's P/B Ratio (75.068) is slightly higher than the industry average of (3.596). P/E Ratio (-35.987) is within average values for comparable stocks, (-1.186). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.158). Dividend Yield (0.000) settles around the average of (131.631) among similar stocks. P/S Ratio (27.548) is also within normal values, averaging (443.347).

The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

Notable companies

The most notable companies in this group are Moderna (NASDAQ:MRNA), Regeneron Pharmaceuticals (NASDAQ:REGN), Incyte Corp (NASDAQ:INCY), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), Sarepta Therapeutics (NASDAQ:SRPT), Novavax (NASDAQ:NVAX), Nektar Therapeutics (NASDAQ:NKTR), Inovio Pharmaceuticals (NASDAQ:INO), Cel-Sci Corp (ASE:CVM).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.24B. The market cap for tickers in the group ranges from 58 to 138.67B. VRTX holds the highest valuation in this group at 138.67B. The lowest valued company is SEELQ at 58.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was -4%. For the same Industry, the average monthly price growth was -12%, and the average quarterly price growth was -25%. VIVS experienced the highest price growth at 111%, while CUE experienced the biggest fall at -74%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was 84%. For the same stocks of the Industry, the average monthly volume growth was 101% and the average quarterly volume growth was 38%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 44
Price Growth Rating: 68
SMR Rating: 93
Profit Risk Rating: 93
Seasonality Score: -4 (-100 ... +100)
1-on-1 3
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a developer of peptide therapeutics for metabolic diseases

Industry Biotechnology

Industry
Biotechnology
Address
222 Berkeley Street
Phone
+1 857 264-4280
Employees
414
Web
https://www.rhythmtx.com
Interact to see
Advertisement
SDD is an inverse leveraged ETF (exchange-traded fund) built to return roughly -2x the daily move of the S&P SmallCap 600 Index, making it a tactical hedging tool rather than a long-term holding. XXX is an asset-allocation ETF that blends roughly 75% S&P 500 large-cap equities with a 25% sleeve of XRP, a major cryptocurrency, aiming for capital appreciation.
AMD jumped +2.42%, rising $12.81 to $542.95 from Wednesday's close of $530.14, in early regular-session trading Thursday after extending gains built during premarket. The catalyst was Anthropic's IPO, priced at $83 a share above its marketed range and raising $81.3 billion in the largest listing on record; the debut revived sentiment across AI hardware names, and AMD is both an Anthropic supplier and a $2.5 billion investor in the lab.
ROM is an established, leveraged exchange-traded fund (ETF) that targets twice (2x) the daily return of the S&P Technology Select Sector Index, while XXX is a recently launched blended ETF pairing large-cap U.S. equities with XRP exposure. ROM benefits from deep liquidity and roughly $1.1 billion in AUM (assets under management); XXX remains far smaller, with assets measured in the hundreds of thousands of dollars.
NVIDIA (NVDA) has declined roughly 32.6% over the last 30 days, falling from $216.47 on October 20 to around $146 in mid-November trading. The selloff was triggered by the surprise resignation of founder and CEO Jensen Huang, along with governance, regulatory, and China-related concerns.
KLAR dropped -4.84% to $13.75 from Wednesday's close of $14.45, with the decline occurring during Thursday's regular session. JPMorgan downgraded the shares to Hold from Overweight and cut its price target to $17 from $20 in a note published before the open, extending a run of post-earnings target reductions.